Discover why Bristol-Myers Squibb's undervalued stock, strong cash flow, and 5% dividend yield make it an attractive buy ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

Meanwhile, Nova One Advisor projects the global oncology drug market will climb to US$366.24 billion by 2034, expanding at a ...

Verve Therapeutics VERV signed a definitive agreement with pharma bigwig Eli Lilly LLY. Per the terms, the pharma giant will ...

China's biotechnology sector is experiencing notable growth, with the ChinaAMC Hang Seng Biotech ETF, tracking the Hang Seng Biotech Index, delivering a 61.55% return over the past year. This ...

BioNTech has announced that it will be expanding its messenger RNA (mRNA) capabilities by acquiring CureVac for approximately $1.25bn. The deal is aimed at strengthening BioNTech’s research, ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy candidates. Analysts say the M&A deal is a way to essentially settle out of court ...

Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its ...

Bristol MyersBMY announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) met its primary endpoint. Sotyktu is an oral, selective tyrosine ...

BioNTech SE (NASDAQ: BNTX) and Bristol Myers Squibb (BMY,“BMS”) recently announced that the companies have entered into an agreement for the global co-development and co-commercialization of ...

Phase III trials of BNT327 are ongoing in extensive-stage small-cell lung cancer and in NSCLC. A phase III trial in triple-negative breast cancer is set to start later this year.